Renal Transplant Rejection Clinical Trial
Official title:
Prospective, Randomized, Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of Immunosuppression Following a Heart-beating Cadaveric Renal Transplantation Based on the Use of Rabbit Anti-T-lymphocyte Serum, Tacrolimus and Mycophenolate, Free of Concomitant Corticosteroids From the Start of Immunosuppression
The main objective of the study is the assessment of the overall graft rejection rate (acute, chronic and subclinical) between a treatment with ATG-Fresenius administered in addition to standard treatment consisting of CellCept® or Myfortic®/TAC and without corticosteroids and a treatment consisting of CellCept® or Myfortic®/TAC and corticosteroids during the first year after renal transplantation.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03140514 -
Urine CXCL10 Chemokine Monitoring Post-renal Transplant
|
N/A | |
Completed |
NCT02581436 -
Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR
|
N/A | |
Active, not recruiting |
NCT02409940 -
To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant Patients
|
Phase 1 | |
Completed |
NCT02377193 -
Simulect Versus ATG in Sensitized Renal Transplant Patient
|
Phase 4 | |
Completed |
NCT00771745 -
Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT05385432 -
Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies
|
Phase 3 | |
Completed |
NCT01953120 -
Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
|
Phase 4 | |
Terminated |
NCT00983645 -
A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity
|
Phase 4 | |
Active, not recruiting |
NCT04530630 -
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant
|
Phase 4 | |
Recruiting |
NCT03707262 -
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
|
Phase 1/Phase 2 | |
Completed |
NCT02006108 -
Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance
|
N/A | |
Recruiting |
NCT03991780 -
Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection
|
Phase 1/Phase 2 | |
Completed |
NCT02733029 -
Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection
|
Phase 2 | |
Active, not recruiting |
NCT02057965 -
Mesenchymal Stromal Cell Therapy in Renal Recipients
|
Phase 2 | |
Completed |
NCT00658073 -
Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts
|
N/A | |
Terminated |
NCT03646344 -
Heme Arginate in Transplantation Study
|
Phase 3 | |
Completed |
NCT02866682 -
Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT06438107 -
Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes
|
||
Completed |
NCT02500251 -
Belimumab Impacting Transplant Eligibility
|
Phase 1/Phase 2 | |
Completed |
NCT00866879 -
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
|
Phase 4 |